GRI BIOPAR Stock

GRI

US3622AW1069

Real-time Estimate Cboe BZX Other stock markets 15:46:47 2026-06-26 EDT			5-day change	1st Jan Change
1.785 ^USD	-8.93%		+4.26%	-72.99%

25-09-11	GRI Bio Says Data Show No Lung Function Decline in Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis	MT
25-04-01	GRI Bio Prices up to $13 Million Equity Offering	MT

Analysts' recommendations: GRI BIOPAR

24-12-09	HC Wainwright Initiates GRI Bio at Buy With $10 Price Target	MT
21-11-22	HC Wainwright Starts Vallon Pharmaceuticals at Buy With $12 Price Target	MT

More recommendations

News in other languages: GRI BIOPAR

22-12-14

MORNING BRIEFING - USA/Asien

More news

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company's lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company's second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
26-06-26	US$1.810	-7.65%	101,279
26-06-25	US$1.960	+6.52%	88,160
26-06-24	US$1.840	-1.08%	92,118
26-06-23	US$1.860	-0.53%	49,764
26-06-22	US$1.870	-0.53%	53,057

Delayed Quote Nasdaq

More quotes

Market Cap	5.39M 4.73M 4.36M 4.08M 7.65M 509M 7.81M 52.39M 20.27M 251M 20.25M 19.81M 872M	P/E 2021	-4.2x	P/E 2022	-0.42x
Enterprise Value	1.61M 1.41M 1.3M 1.22M 2.29M 152M 2.33M 15.66M 6.06M 75.15M 6.05M 5.92M 261M	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	-	Yield 2021 *	-	Yield 2022	-

25-09-11	GRI Bio Says Data Show No Lung Function Decline in Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis	MT
25-04-01	GRI Bio Prices up to $13 Million Equity Offering	MT
25-02-20	Top Midday Decliners	MT
24-12-09	HC Wainwright Initiates GRI Bio at Buy With $10 Price Target	MT
24-10-22	Top Midday Decliners	MT
24-10-22	Wall Street Set to Open Lower as Investors Await Earnings Report, Harker Speech	MT
24-10-22	Investors Await Earnings Reports as US Futures Move Lower Tuesday Pre-Bell	MT
24-10-22	GRI Bio Agrees to Exercise of Warrants at Reduced Price; Shares Fall Premarket After Doubling on Monday	MT
24-10-21	Top Premarket Gainers	MT
24-09-30	GRI Bio Gets Japan Patent for Natural Killer T Cell Modulators to Prevent, Treat Inflammatory Diseases	MT
24-07-08	GRI Bio Regains Nasdaq Compliance	MT
24-06-26	Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	MT
24-06-26	Top Premarket Decliners	MT

06-18	GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis	AQ
05-18	GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase	AQ
05-14	GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline	AQ
04-08	GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions	AQ
02-17	GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment	AQ

5 years	1.75		310.8
10 years	1.75		310.8

	2021	2022
Net sales	-	-
Net income	-9.3M -8.16M -7.52M -7.04M -13.2M -878M -13.47M -90.37M -34.97M -434M -34.93M -34.17M -1.5B	-7.02M -6.16M -5.68M -5.31M -9.97M -663M -10.17M -68.23M -26.4M -327M -26.38M -25.8M -1.14B
Net Debt	-7.34M -6.44M -5.93M -5.55M -10.42M -692M -10.63M -71.31M -27.59M -342M -27.57M -26.96M -1.19B	-3.78M -3.32M -3.06M -2.86M -5.36M -357M -5.48M -36.73M -14.21M -176M -14.2M -13.89M -611M

GRI BIOPAR Stock

Stocks

GRI

US3622AW1069

Valuation: GRI BIOPAR

Chart: GRI BIOPAR

Latest news : GRI BIOPAR

Analysts' recommendations: GRI BIOPAR

Press Releases: GRI BIOPAR

News in other languages: GRI BIOPAR

Quotes and Performance

Course Extremes

Financials

Company Profile

Quotes

1 day	-8.93%
Current month	-72.99%
Current year	-72.99%